What laboratory tests should be obtained to evaluate and monitor a patient with suspected multiple myeloma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Laboratory Tests for Multiple Myeloma Evaluation

For suspected multiple myeloma, obtain a comprehensive laboratory panel including: complete blood count, chemistry screen with calcium and creatinine, serum protein electrophoresis with immunofixation, nephelometric quantification of immunoglobulins, 24-hour urine collection for protein electrophoresis and immunofixation, serum free light chains, beta-2 microglobulin, LDH, and bone marrow aspirate/biopsy with cytogenetics (FISH and metaphase karyotype). 1, 2

Essential Blood Tests

Hematologic and Chemistry Panel

  • Complete blood count with differential and peripheral smear - Look for anemia (hemoglobin <10 g/dL or ≥2 g/dL below normal), Rouleaux formation on smear indicating elevated serum proteins 1, 2
  • Chemistry screen including:
    • Serum calcium (hypercalcemia defined as ≥11.5 mg/dL is a CRAB criterion) 1
    • Serum creatinine (renal insufficiency ≥2 mg/dL is a CRAB criterion) 1
    • Creatinine clearance (calculated or measured directly) 2
    • Serum electrolytes, liver function tests, albumin 2

Protein Studies - The Diagnostic Cornerstone

  • Serum protein electrophoresis (SPEP) with immunofixation (SIFE) - Identifies and characterizes the monoclonal protein (M-protein), which is required for diagnosis except in nonsecretory myeloma 1, 2
  • Nephelometric quantification of serum immunoglobulins - Provides accurate measurement of M-protein concentration, though may overestimate when values are high 1
  • Serum free light chain (FLC) assay with kappa/lambda ratio - High sensitivity for screening, required for documenting stringent complete response, and essential when involved/uninvolved FLC ratio ≥100 (with involved FLC ≥100 mg/L) as this alone can define myeloma 2, 3

Critical caveat: The serum FLC assay cannot replace 24-hour urine collection for monitoring patients with measurable urinary M-protein and is affected by renal function 2.

Urine Studies - Do Not Skip These

  • 24-hour urine collection for total protein, urine protein electrophoresis (UPEP), and urine immunofixation (UIFE) - This is mandatory once myeloma is suspected, not optional 1
  • Immunofixation must be performed even if no measurable protein or peak is seen on electrophoresis 1
  • Random urine samples corrected for creatinine cannot replace 24-hour collection 1

Important pitfall: Urine free light chain assay should NOT be performed - only serum FLC testing is recommended 1.

Prognostic and Staging Markers

  • Beta-2 microglobulin - Reflects tumor burden and renal function, essential for International Staging System 1, 2
  • Lactate dehydrogenase (LDH) - Reflects tumor cell characteristics and proliferation 2
  • Serum albumin - Component of staging system; bromcresol method correlates well with nephelometric quantitation and is independent of M-protein levels 1

Bone Marrow Evaluation - Confirms the Diagnosis

Unilateral bone marrow aspirate and/or biopsy is required to confirm ≥10% clonal plasma cells (≥60% is itself a myeloma-defining event) 1, 3. The trephine biopsy should be performed alongside aspirate because: (1) it provides more reliable assessment of plasma cell infiltration, and (2) it prevents need for repeat procedure if aspirate is inadequate 1.

  • CD138 immunohistochemistry should be used when possible to accurately determine plasma cell percentage 1
  • Immunoperoxidase staining or immunofluorescence establishes clonality by identifying monoclonal immunoglobulin in plasma cell cytoplasm 1
  • Record the highest plasma cell percentage from either aspirate or biopsy 1

Cytogenetic Studies - Risk Stratification

Both FISH and metaphase cytogenetics are required at initial assessment 1, 2:

FISH (on sorted plasma cells, preferably)

  • Deletion 17p13 (p53 locus) - high-risk feature 2, 3
  • t(4;14) - high-risk, especially with gain(1q) or del(1p) 3
  • t(14;16) - high-risk, especially with gain(1q) or del(1p) 3
  • t(14;20) - high-risk when combined with gain(1q) or del(1p) 3
  • Gain(1q) plus del(1p) - defines high-risk 3
  • Bi-allelic del(1p) - high-risk feature 3

Metaphase Cytogenetics

Despite low yield (~20%), this captures hyperdiploid versus non-hyperdiploid status and uncommon translocations, deletions, and amplifications that provide prognostic information 1.

Algorithmic Approach to Testing

  1. Initial screening: CBC, chemistry with calcium/creatinine, SPEP with immunofixation, serum FLC
  2. If M-protein detected or high clinical suspicion: Add 24-hour urine collection with UPEP/UIFE, nephelometric immunoglobulin quantification, beta-2 microglobulin, LDH
  3. To confirm diagnosis: Bone marrow aspirate/biopsy with CD138 staining, FISH panel, metaphase cytogenetics
  4. For monitoring: Use the same test method for serial M-protein measurements to ensure accurate quantification 2

The combination of normal hemoglobin with normal plasma viscosity or ESR has excellent rule-out value (LR- = 0.12) in primary care settings 4, but this does not replace the full diagnostic workup when myeloma is suspected.

References

2
Guideline

multiple myeloma, version 3.2021, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2020

4
Research

Early detection of multiple myeloma in primary care using blood tests: a case-control study in primary care.

The British journal of general practice : the journal of the Royal College of General Practitioners, 2018

Related Questions

What is the recommended treatment regimen for a newly diagnosed adult with multiple myeloma, including induction therapy, transplant eligibility, supportive care, and relapse options?
Which laboratory tests should be ordered to diagnose multiple myeloma?
What are the guideline‑recommended diagnostic work‑up and management strategies for multiple myeloma, including initial evaluation, risk‑adapted therapy, maintenance, supportive care, and relapse treatment?
What diagnostic work‑up and initial treatment should be undertaken for a patient with a high likelihood of multiple myeloma and a serum free light chain (lambda) level of 114?
What diagnostic test confirms multiple myeloma?
Do basic metabolic panel (BMP) and comprehensive metabolic panel (CMP) require fasting?
In a 53-year-old woman with dense breast tissue, will prescribing a transdermal estrogen patch and 100 mg oral progesterone increase breast density or affect mammographic visualization?
Can an SGLT‑2 inhibitor be initiated in an adult with type 2 diabetes and an estimated glomerular filtration rate of 31 mL/min/1.73 m²?
Can exposure to perchloroethylene (PCE), trichloroethylene (TCE), vinyl chloride, and benzene in contaminated water cause hypertension years after exposure?
What is the mechanism of action of metolazone as a diuretic?
In an inpatient setting, how should uncontrolled withdrawal be treated with lorazepam (Ativan) PRN, including recommended dose and dosing frequency?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.